Do pharmacokinetics justify dose-optimization for loss of response to Vedolizumab in IBD?

Abstract

Knowledge surrounding therapeutic drug monitoring (TDM) in inflammatory bowel disease is growing, especially for tumor necrosis factor-? inhibitors class of drugs. Yet, TDM for the ?4?7 integrin antibody vedolizumab (VDZ) has not been equally established, as real-life data on VDZ pharmacokinetics, VDZ drug level and treatment response are scarce.
 We summarize the @GIJournal discussion held on July 14, 2021 during which the article by Ungar et al. “Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms” was critically reviewed by our expert Dr. Aline Charabaty (AC), and moderated by Dr. Asad ur Rahman (AR).